S.A. Team

About the Author S.A. Team

Smarter Analyst was established to fill a gap in financial reporting for sell-side investors, where they can read exclusive reports in real time. Smarter Analyst provides coverage of equities research, unique analyst insights, and outstanding articles from knowledgeable contributors, in addition to the latest stock market news, all hand-picked by our editors.

Deutsche Bank Pinpoints Uncertainties Nipping at Valeant’s Potential for Growth

Valeant Pharmaceuticals (NYSE:VRX) aced its third quarter, but while many on Wall Street were thrilled …

Read more

Maxim Bull Says xG Technology Will Make Up for 3Q Miss with 4Q Growth Recovery

xG Technology Inc (NASDAQ:XGTI) did not put its best foot forward during a third quarter …

Read more

Mizuho Wonders if Teva Can Avoid Downgrade to High Yield After Rocky 3Q Print

Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina …

Read more

Aurinia Has Canaccord Captivated with Voclosporin Prospects

Following a third quarter print and clinical update from Aurinia Pharmaceuticals (NASDAQ:AUPH) on its pivotal …

Read more

Calithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer Data

According to an abstract released on November 13th, Calithera’s (NASDAQ:CALA) Triple-Negative-Breast-Cancer appears to show a …

Read more

Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia

Billionaire Israel “Izzy” Englander, who helmed his fortune from humble, Polish immigrant beginnings took a …

Read more

J.P. Morgan Says Acorda Troubling Parkinson’s Trial Lessens Upside Potential

Acorda Therapeutics Inc (NASDAQ:ACOR) shareholders are spooked right now after the drug maker confirmed yesterday …

Read more

H.C. Wainwright Likes Aurinia Pharmaceuticals’ Opportunity at Hand in the Lupus Nephritis Market

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has enticing clinical potential that has caught the eyes of more …

Read more

Synergy Pharmaceuticals: Should You Buy the Dip Ahead of FDA Approval?

Shares of biopharma Synergy Pharmaceuticals (NASDAQ:SGYP) are now almost half the price one month ago …

Read more

Oppenheimer Gets Bearish on Pricey Roku Stock

Roku Inc (NASDAQ:ROKU) had just had quite the earnings party, with investors sending shares skyrocketing …

Read more